Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03179449 : In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI
PhaseEarly Phase 1
AgesMin: 2 Years Max: N/A
Eligibility
Inclusion Criteria:

- Any patient with suspected malignant brain tumor on diagnostic MR imaging who will
undergo a resection

Exclusion Criteria:

- Informed consent cannot be obtained either from the patient or legal representative

- Severe coexisting or terminal systemic disease that may interfere with the conduct of
the study

- Contraindication to MRI (metal implants)

- Hemosiderosis/hemochromatosis

- Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if
secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or
parenteral iron, or any other etiology

- Known hypersensitivity to ferumoxytol or any of its components

- Pregnant patients
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03179449      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740